Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy
Condition: Diabetic; Neuropathic, Polyneuropathy (Manifestation)
MeSH terms: Diabetic Neuropathies; Polyneuropathies
Study type: Interventional
Phase: Phase 3

Summary: 
      Investigators propose a placebo controlled, double blinded study to examine efficacy of
      topical Gelnique 3%TM (3% oxybutynin) daily for 20 weeks) in improving IENF density in type 2
      diabetic subjects with established peripheral neuropathy. This site most clearly demonstrated
      efficacy of topiramate in reversing IENF loss within 18 weeks in our prior study. Subjects
      will also undergo quantitative sensory testing (QST) and assays of laser Doppler skin blood
      flow (SkBF), neuropathy total symptom score (NTSS-6), and quality of life (Norfolk QOL-DN),
      along with standard measures of physiology and fasting blood chemistry. Subjects with IENF
      loss of between 20-75% of normative values and thus amenable to therapy-induced recovery,
      will be randomized into placebo (N=30) or active drug (N=30) arms and instructed in how to
      apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the
      initial biopsy site, as per the manufacturers instructions (http://www.gelnique.com/gel3/).
      Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
      After 20 weeks, subjects will return for a second series of measurements and 3 mm skin biopsy
      from the treated region of skin.
    

Detailed description: 
      Patient selection and characterization A total of 60 adults of both sexes and varying
      ethnicities, 30-80 years of age, will be recruited from Dr. Vinik's clinic. All participants
      will be diagnosed with established type 2 diabetes (>2 years) and diabetic peripheral
      neuropathy. Potential subjects will undergo a complete physical exam and a neurological exam
      to assess motor function and sensory perception28.

      Randomizing and blinding an investigational drug will be done by assigning each
      patient/subject a study number in the order they are recruited. The patients are randomized
      using a randomizing web site at (www.randomizer.org). The randomized patient numbers are
      recorded. This code is then placed in an envelope and sealed. This envelope will remain
      sealed until the study is concluded. A blinding/randomization patient form will be completed
      for each patient and sealed in the individual envelopes. The outside of the envelopes will
      contain patient numbers for identification purposes. This will allow the research coordinator
      to break the individual blind in emergency situations without compromising the rest of the
      blinding data. All instances where the blind is broken will be documented appropriately.

      Subject Recruitment Subjects of both sexes and all ethnicities will be recruited locally
      using the database of subjects available at The Strelitz Diabetes Research Center (SDRC) at
      Eastern Virginia Medical School (EVMS) as well as locally distributed flyers and notices, if
      needed. Approximately 60 randomized subjects are needed in this study to make a useful
      determination for current and future studies. Subjects who are dropped or withdraw from the
      study will be replaced.

      Sample size estimation and data analysis:

      Investigators have primarily powered the study based on variance data obtained in studies
      demonstrating efficacy of Topiramate on IENF density in diabetic subjects11. The sample size
      of 20 in each group (placebo vs. active drug) reflects the ability to detect a 20% deviation
      following treatment and was also sufficient to to identify therapy-induced improvements in
      SkBF and NTTS-6 score using a similar study design28. We intend to use ANOVA and MANOVA where
      data is normally distributed in raw form or in some cases after simple log-transformations.
      Based on these considerations, the 20 subjects in each group provide power greater than 0.80
      for observing statistical significance at the p < 0.05 level. Relationships among measures of
      neurovascular function and changes in IENF will be determined with Spearman's rank
      correlation. If data are not normally distributed, the Wilcoxon signed-rank (within group) or
      Mann Whitney (between group) tests may be employed. The level of significance will be set at
      p<0.05.

      FUTURE USE OF BIOLOGICAL SPECIMENS AND BANKING PROTOCOL After all of the required tests are
      finished, subjects will be asked if their leftover specimen may be stored for future research
      instead of throwing it away. Subjects will be asked to sign an addendum IRB approved consent
      form (#07-08-FB-0167) that allows the storage of biological specimen. An IRB application will
      be submitted for the use of any stored samples.

      Study activity will take place after review and approval by the EVMS IRB (or other approved
      IRB). The IRB has the fundamental charge of protecting the rights and welfare of human
      participants in research. The EVMS Federal Wide Assurance assures that all research
      activities are guided by the ethical principles of The Belmont Report (respect for persons,
      beneficence, and justice) and activities comply with 45CFR46, regardless of funding source.
      These principles will be implemented through the process of informed consent by sharing
      information, ensuring subject comprehension and selecting volunteers without coercion or
      undue influence.

      SAFETY EVALUATIONS AND ADVERSE EVENT REPORTING

      Adverse events (AE's) will be recorded for all subjects. Relationship to study procedures
      performed will be documented by the investigator. Serious Adverse Events (SAEs) and
      pregnancies, which occur during this study, will be reported immediately upon their discovery
      to all appropriate agencies (Institutional Review Board (IRB). Serious Adverse Events are
      defined as any adverse event from this study that results in one of the following outcomes,
      or is significant for any other reason:

        -  Death

        -  Initial or prolonged inpatient hospitalization

        -  A life-threatening experience (that is, immediate risk of dying)

        -  Persistent or significant disability/incapacity

        -  Congenital anomaly/birth defect

      The principal investigator will review the safety and progress of this study on a monthly
      basis. The principal investigator will review this protocol on a continuing basis for subject
      safety.

      Risks and Protection Against Risk All subjects will be monitored for adverse and/or
      unexpected events. All information and data are kept in strict confidence. No information
      will be given to anyone without permission from the study participant.

      Risks to participants will be minimized through subject selection, documented informed
      consent from the study participant, provisions made for the protection of privacy and
      confidentiality of data, and data monitoring to ensure subject safety. Data will be coded so
      that linkages to participants will only be available to the investigators. The database will
      be password protected and only the investigative staff will have access to the database. All
      subject names and personally identifiable data will be coded so that personal information
      (e.g., name, social security number, drivers' license number, address and phone number)
      remains private. Only the study investigators will have access to the information.
      Participants will not be personally identified in reports or publications.

      Reproductive Risk Gelnique 3% is classified as a pregnancy category class B drug. Animal
      reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate
      and well-controlled studies in pregnant women. Serum HcG testing for pregnancy will be
      performed at the screening. All participants will be asked to use birth control such as
      barrier methods (i.e. condoms, diaphragms), oral contraceptives, or intrauterine devices if
      they have not been surgically sterilized. Pregnancies will be treated as adverse events and
      will be followed to term.

      Database Protection All data will be locally monitored according to the Strelitz Diabetes
      Center Standard Operating Procedures (see procedures below) and standard precautions will be
      made to protect personal health information.

        1. Assign unique and secure User ID/password combination for each clinical research team
           member who has access to the computerized system(s). Ensure that users login using this
           unique User ID/password combination or other electronic signature when preparing to
           perform computer data entry or management functions.

        2. Establish and maintain a schedule for changing each team member's User ID/password
           combination at appropriate intervals.

        3. Invalidate stolen, lost or otherwise compromised User ID/password combinations and
           replace with a new combination.

        4. Ensure that proper computer system function is routinely monitored.

        5. Ensure that computerized systems are securely stored when not in use.

        6. Log off when computer data entry/management activities are completed.
    

Intervention name(s): 3% oxybutynin; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.; Non-active placebo for 3% oxybutynin
Other intervention name(s): Gelnique 3%TM
Intervention MeSH terms: Oxybutynin
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: The investigators propose a placebo controlled, double blinded study to examine efficacy of topical Gelnique 3%TM (3% oxybutynin) daily for 20 weeks) in improving IENF density in type 2 diabetic subjects with established peripheral neuropathy. Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into placebo (N=30) or active drug (N=30) arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site, as per the manufacturers instructions (http://www.gelnique.com/gel3/). Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance. After 20 weeks, subjects will return for a second study visit and will undergo a series of measurements and 3 mm skin biopsy from the treated region of skin.
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment